TechsoMed is a technology company.
TechsoMed has raised $10.0M across 2 funding rounds.
TechsoMed has raised $10.0M in total across 2 funding rounds.
TechsoMed is a medical technology company specializing in AI-powered image-guided ablation therapy, primarily through its BioTrace™ platform. This platform integrates with standard commercial ultrasound imaging systems to provide real-time visualization and analysis of tissue viability during thermal ablation procedures, which are minimally invasive treatments used in oncology (tumor ablation), cardiology (heart arrhythmia), and pain management. By enabling physicians to see tissue response immediately during procedures, TechsoMed’s technology aims to improve treatment precision, safety, and outcomes while reducing costs and expanding patient access[1][2][3].
The company serves hospitals, physicians, and healthcare providers involved in thermal ablation therapies. Its products, including the FDA-cleared BioTraceIO™ Vision and BioTraceIO™ Precision software, support enhanced clinical decision-making and procedural efficiency. TechsoMed has demonstrated growth momentum through FDA approvals, international expansion (notably in Japan and Germany), and ongoing clinical validations, positioning itself as a leader in AI-driven ablation therapy solutions[1][2][4].
Founded in 2012 in Rehovot, Israel, TechsoMed was established by CEO Yossi Abu and his team with a vision to revolutionize thermal ablation therapy by integrating AI and real-time imaging. The idea emerged from the need to eliminate the guesswork in ablation procedures, which traditionally rely on delayed imaging feedback. Early pivotal moments include the development of the BioTrace platform, securing FDA clearances for its software products, and forming strategic partnerships such as the joint venture in Japan with Axil Capital and Screen Holdings to accelerate regulatory approval and market entry in Asia[1][3][4].
TechsoMed rides the growing trend of AI integration in medical imaging and minimally invasive therapies, addressing the critical need for precision medicine and real-time procedural feedback. The timing aligns with increasing adoption of thermal ablation as a less invasive alternative to surgery and the healthcare sector’s push for cost-effective, patient-friendly treatments. Market forces such as rising cancer incidence, demand for outpatient procedures, and regulatory support for AI medical devices favor TechsoMed’s growth. By enhancing ablation accuracy and safety, TechsoMed influences the broader ecosystem by setting new standards for image-guided interventions and expanding the role of AI in clinical decision support[1][3][4].
Looking ahead, TechsoMed is poised to expand its global market presence through further regulatory approvals, especially in Asia and Europe, and by broadening its product suite with the upcoming BioTraceIO™ 360 all-in-one system. Trends shaping its journey include advances in generative AI, increasing demand for personalized treatment planning, and the shift toward outpatient and minimally invasive procedures. As the company scales, its influence may extend beyond ablation therapy into other image-guided interventions, potentially transforming multiple clinical domains. TechsoMed’s commitment to innovation and strategic partnerships suggests it will remain at the forefront of AI-driven medical imaging technologies, continuing to enhance patient outcomes and procedural efficiency[1][3][4].
TechsoMed has raised $10.0M in total across 2 funding rounds.
TechsoMed's investors include 4BIO Capital, Astellas Venture Management, Axil Capital, Remiges Ventures.
TechsoMed has raised $10.0M across 2 funding rounds. Most recently, it raised $7.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $7.0M Series B | 4BIO Capital, Astellas Venture Management, Axil Capital, Remiges Ventures | |
| May 1, 2019 | $3.0M Venture Round | 4BIO Capital, Astellas Venture Management, Axil Capital, Remiges Ventures |